Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

Clinical Therapeutics

Volumn 21, Issue 2, 1999, Pages 309-318

  Goldenberg, Marvin M ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

HER2 overexpression; Metastatic breast cancer; rhuMabHER2; Trastuzumab

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR; GENE PRODUCT; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CAUSE OF DEATH; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DYSPNEA; FEMALE; FEVER; GENE OVEREXPRESSION; HUMAN; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RHINITIS; STEADY STATE; TUMOR GROWTH;

EID: 0032895235     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88288-0     Document Type: Article

References (28)

1. 1. Wingo PA, Ries LA, Rosenberg HM, et al. Cancer incidence and mortality, 1973-1995. Cancer. 1998;82:1197-1207.
2. 2. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. Ca Cancer J Clin. 1998;48:6-29.
3. 3. Ries LA, Kosary CL, Hankey BF, et al. SEER cancer statistics review, 1973-1994. N1H Publication no. 97-2789. Bethesda, Md: National Cancer Institute; 1997:1-55.
4. 4. Honig SL. Treatment of metastatic disease. In: Harris JK, ed. Diseases of the Breast. Philadelphia, Pa: Lippincott-Raven; 1996:669-734.
5. 5. Chu KC, Tarone RE, Kessler LG, et al. Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Lancer Inst. 1996;88:1571-1579.
6. 6. Aaronson SA. Growth factors and cancer. Science. 1991;254:1146-1153.
7. 7. Harris JR, Lippman ME, Veronesi U, et al. Breast cancer. NEJM. 1992;327:473-480.
8. 8. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HKR-2/neu oncogene. Science. 1987;235:177-182.
9. 9. Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16:462-469.
10. 10. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
11. 11. Hynes NE, Stem DF. The biology of erb-2/ neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1994;1198:165-184.
12. 12. Kraus MH, Issing W, Miki T, et al. Isolation and characterization of ErB3, a third member of the erb/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. Proc Nail Acad Sci USA. 1989;90:9193-9197.
13. 13. Plowman CD, Culouscou JM, Whitney GS. Ligand-specific activation of HER-4/ p180erbB4, a fourth member of the epidermal growth factor family. Proc Natl Acad Sci USA. 1993;90:1746-1750.
14. 14. Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cisdiaminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991;51:4575-4580.
15. 15. Stancovski I, Hurwitz E, Leitner D, et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the erB-2 receptor on tumor growth. Proc Natl Acad Sci USA. 1991;88:8691-8695.
16. 16. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285-4289.
17. 17. Coussens L, Yang-Feng TL, Liao Y-C, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132-1139.
18. 18. Yokota J, Yamamoto N, Miyajima K, et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinorna of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene. 1988;2:283-287.
19. 19. Hudziak RM, Lewis GD, Winget M, et al. P185HER2 monoclonal antibody has antiproliferative effects in vivo and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989;9:1165-1172.
20. 20. Kraus MH, Popescu NC, Amsbaugh C, et al. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary rumor cell lines by different molecular mechanisms. EMBO J. 1987;6:605-610.
21. 21. Haigler H, Ash JF, Singer J, et al. Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells. Proc Natl Acad Sci USA. 1978;75:3317-3321.
22. 22. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185 HER2 monoclonal antibodies. Cancer Immunol Immunother. 1993;37:255-263.
23. 23. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994;9:1829-1838.
24. 24. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts, Cancer Res. 1998;58:2825-2831.
25. 25. Data on file. Genentech, Inc. HHS U.S. license #1048;1998.
26. 26. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737-744.
27. 27. Cobleigh M. Efficacy and safety of herceptin (humanized anti-HER-2 antibody) as a single agent in 222 women with HER-2 overexpression who relapsed following chemotherapy for metastatic breast cancer. In: Program and abstracts of the American Society of Clinical Oncology meeting. 1998;17:376. Abstract.
28. 28. Slamon DJ, Leyland-Jones B, Shak S, et al. Addition of herceptin (humanized anti-HER-2 antibody) to first line chemotherapy for HER-2 overexpressing metastatic breast cancer markedly increases anti-cancer activity: In: Program and abstracts of the American Society of Clinical Oncology meeting. 1998;17:377. Abstract.